Equity capital markets bankers staring glumly at the US$217 million balance raised via Australian IPOs so far this year could soon have a new crop of clients: U.S. biotech companies and device-makers.
Californian sleep apnea device-maker Ventus Medical is currently raising A$40 million as part of its IPO while Minnesota’s Osprey Medical joined the Australian Securities Exchange on May 2, and – unlike Facebook — has held onto its offer price of 40 cents a share.
